Ng Loretta T, Tong Judy W, De Land Paul N
Southern California College of Optometry, Fullerton 92831, USA.
Cornea. 2006 Jul;25(6):679-86. doi: 10.1097/01.ico.0000214233.74603.ce.
To evaluate the safety, validity, and comfort of 0.35% fluorexon disodium and 0.4% benoxinate (Flura-Safe) compared with the gold standard of 0.25% sodium fluorescein and 0.4% benoxinate for Goldmann applanation tonometry (GAT).
This was a double-masked, randomized, crossover clinical trial. Subjects received either the standard or study formulation for GAT on visit 1 and the other formulation 1 week later. At each visit, tonometer mire quality, adequacy of fluorescence, ease of intraocular pressure (IOP) measurements, the IOP value, and anesthetizing efficacy of the formulation were assessed. Subjects graded general comfort, soreness and irritation, and burning and stinging of each formulation at 1 and 5 minutes after drop instillation.
Sixty-seven subjects completed the study. The mean IOP was 13.9 +/- 2.7 with fluorexon and 13.9 +/- 2.8 mm Hg with fluorescein OD and 14.0 +/- 2.8 with fluorexon and 13.9 +/- 2.5 mm Hg with fluorescein OS. The measurements with the 2 formulations were highly correlated for OD and OS, and the differences between the 2 measurements were not clinically significant. There was also no significant difference between the 2 drops in mire clarity, adequacy of fluorescence, or corneal anesthesia. However, fluorexon was statistically more comfortable (P = 0.039) and caused less stinging and burning (P = 0.014) at 1 minute versus the fluorescein formulation.
Not only was the new fluorexon product accurate and effective in GAT, it was also statistically more comfortable and had a less stinging and burning effect at 1 minute after drop instillation than the traditional fluorescein formulation. Because fluorexon is less likely to stain soft contact lenses, this may be the dye-anesthetic formulation of choice for practices that routinely perform GAT.
将0.35%荧光素钠和0.4%丁卡因(氟乐卡因)与用于Goldmann压平眼压计(GAT)的0.25%荧光素钠和0.4%丁卡因的金标准进行比较,评估其安全性、有效性和舒适度。
这是一项双盲、随机、交叉临床试验。受试者在第1次就诊时接受用于GAT的标准制剂或研究制剂,1周后接受另一种制剂。每次就诊时,评估眼压计视标质量、荧光充足度、眼压(IOP)测量的难易程度、IOP值以及制剂的麻醉效果。受试者在滴药后1分钟和5分钟对每种制剂的总体舒适度、酸痛和刺激感以及灼烧和刺痛感进行评分。
67名受试者完成了研究。使用荧光素钠时右眼平均眼压为13.9±2.7 mmHg,使用荧光素时右眼平均眼压为13.9±2.8 mmHg;使用荧光素钠时左眼平均眼压为14.0±2.8 mmHg,使用荧光素时左眼平均眼压为13.9±2.5 mmHg。两种制剂的测量结果在右眼和左眼高度相关,两种测量之间的差异无临床意义。两种滴眼液在视标清晰度、荧光充足度或角膜麻醉方面也无显著差异。然而,与荧光素制剂相比,荧光素钠在1分钟时在统计学上更舒适(P = 0.039),且引起的刺痛和灼烧感更少(P = 0.014)。
新型荧光素钠产品不仅在GAT中准确有效,而且在统计学上更舒适,与传统荧光素制剂相比,滴药后1分钟时的刺痛和灼烧感更小。由于荧光素钠染软质隐形眼镜的可能性较小,这可能是常规进行GAT的医疗机构首选的染料 - 麻醉制剂。